Veryan | Press Release



Novel 3D Stent Demonstrates Safety and Efficacy at Nine Months in Treatment of PAD

Barcelona, Spain, 9 May 2013 – Data presented here today at the 10th International Symposium on Endovascular Therapeutics (SITE) show that a stent with unique three-dimensional geometry, BioMimics 3D™, has demonstrated an excellent safety profile and promising clinical performance at nine months in the treatment of patients with peripheral arterial disease (PAD) undergoing femoropopliteal artery intervention.

The MIMICS study is a prospective, randomised controlled trial, conducted at eight German investigational centres, comparing the safety and efficacy of the BioMimics 3D™ stent with a straight nitinol stent (primarily the Bard LifeStent) in patients with PAD undergoing femoropopliteal artery intervention. Fifty patients initially received treatment with the BioMimics 3D™ stent and 26 with the control stent.

Nine-month data, presented by Professor Peter Gaines, Sheffield Vascular Institute, Sheffield, UK, showed that 98% of the remaining patients (46 out of 47) treated with BioMimics 3D stents were free from clinically-driven target lesion revascularisation (CD TLR), compared with 92% (24 out of 26) from the control group. No stent fractures were detected by the independent core lab in either treatment group.

Professor Gaines presented the features of the BioMimics 3D stent which has a unique design featuring 3D curvature that closely mimics the natural helical geometry of the human vascular system. This stent is designed to improve blood flow, potentially conferring a vasoprotective effect, and enhances bio-mechanical performance, to reduce stent fracture, kinking, deformation and subsequent vessel trauma during leg flexion, compared to a standard straight nitinol stent.

“Besides reducing the risk of stent fracture, the unique BioMimics 3D stent architecture has been shown in preclinical animal studies to transform a laminar flow into a swirling flow, a phenomenon known to increase wall shear stress, which may mitigate the development of neointimal hyperproliferation”, commented Professor Gaines. “The nine-month results of the trial have proven the safety of the new stent design, and we are eagerly awaiting the twelve-month patency results, due to be presented at EuroPCR in a few weeks’ time.”

Veryan received CE Mark approval for the BioMimics 3D stent in November 2012.

-Ends-

Media contact:

Richard Kenyon
richard@rkpr.co.uk
+44 7831 569940

Veryan | Press Release



About Veryan

Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan's BioMimics 3D™ stent technology involves adapting traditional straight stent designs to a three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology is designed to enhance clinical performance by improving flow conditions in, and bio-mechanical performance of, stented vessels.

Pre-clinical studies have shown that BioMimics 3D stent technology may significantly reduce restenosis (the narrowing of stented arterial segments) and confer significant mechanical benefits: the BioMimics 3D stent is more flexible, kink and fracture resistant than conventional counterparts.

To date, Veryan has received venture investments totalling GBP 17.7 million from Imperial Innovations, Seroba Kernal, Oxford Gateway, Nikko Principal and NESTA.

CAUTION: The BioMimics 3D stent is not available for sale or investigational use in the United States.

For further information, please visit: www.veryanmed.com